Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants

New England Journal of Medicine

Volumn 356, Issue 13, 2007, Pages 1344-1351

  Hendeles, Leslie ^a,e   Colice, Gene L ^b,c   Meyer, Robert J ^d  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLOROFLUOROCARBON; PROPELLANT; SALBUTAMOL;

AIR POLLUTION; ASTHMA; BRONCHOSPASM; CANCER RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG USE; EUROPE; HEALTH HAZARD; HUMAN; LAW; METERED DOSE INHALER; PRIORITY JOURNAL; REVIEW; ULTRAVIOLET B RADIATION; UNITED STATES;

EID: 34047146927     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra050380     Document Type: Review

References (49)

1. Food and Drug Administration. Use of ozone-depleting substances: removal of essential-use designations. Fed Regist 2004;69(115):33602-18.
2. United Nations Environment Programme. Progress report of the Technology and Economic Assessment Panel. Table 2.3. Nairobi: UNEP, May 2006. (Accessed March 5, 2007, at http://ozone.unep.org/Teap/Reports/TEAP_Reports/TEAP-Progress- Report-may2006.pdf.)
3. Idem. Use of ozone-depleting substances; removal of essential-use designations: final rule. Fed Regist 2005;70:17167-92.
4. Lovelock JE. Atmospheric fluorine compounds as indicators of air movements. Nature 1971;230:379.
5. Molina MJ, Rowland FS. Stratospheric sink for chlorofluorocarbons: chlorine atom catalysed destruction of ozone. Nature 1974;249:810-4.
6. Lloyd SA. Stratospheric ozone depletion. Lancet 1993;342:1156-8.
7. West SK, Duncan DD, Munoz B, et al. Sunlight exposure and risk of lens opacities in a population-based study: the Salisbury Eye Evaluation project. JAMA 1998;280:714-8.
8. Solar radiation and human health. Fact sheet no. 133. Geneva: World Health Organization, September 1996.
9. United Nations Environmental Programme. The Montreal Protocol on substances that deplete the ozone layer. Nairobi: UNEP, 2000. (Accessed March 5, 2007, at http://www.unep.org/ozone/pdfs/montreal-protocol2000.pdf.)
10. Center for Drug Evaluation and Research. Electronic Orange Book: approved drug products with therapeutic equivalence evaluations. Rockville, MD: Food and Drug Administration, August 2006. (Accessed March 5, 2007, at http://www.fda.gov/cder/ob/default.htm.)
11. June D. Achieving the change: challenges and successes in the formulation of CFC-free MDIs. Eur Respir Rev 1997;7:32-4.
12. Barry PW, O'Callaghan C. In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices. Eur Respir J 1997;10:1345-8.
13. Cheng YS, Fu CS, Yazzie D, Zhou Y. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. J Aerosol Med 2001;14:255-66.
14. Harrison LI, Cline A, Wells TM, et al. Systemic concentrations of salbutamol and HFA-134a after inhalation of salbutamol sulfate in a chlorofluorocarbon-free system. Ther Drug Monit 1996;18:240-4.
15. Clark DJ, Lipworth BJ. Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 1996;41:247-9.
16. Joguparthi V, Breen P, Compadre C, et al. Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects. J Aerosol Med 2003;16:47-53.
17. Lipworth BJ, Clark DJ. Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices. Br J Clin Pharmacol 1998;46:45-8.
18. Pierart F, Wildhaber JH, Vrancken I, Devadason SG, Le Souef PN. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J 1999;13:673-8.
19. Anhoj J, Bisgaard H, Lipworth BJ. Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. Br J Clin Pharmacol 1999;47:333-6.
20. Lugo RA, Kenney JK, Keenan J, Salyer JW, Ballard J, Ward RM. Albuterol delivery in a neonatal ventilated lung model: nebulization versus chlorofluorocarbon- and hydrofluoroalkane-pressurized metered dose inhalers. Pediatr Pulmonol 2001;31:247-54.
21. Bamber MG. Difficulties with CFC-free salbutamol inhaler. Lancet 1996;348:1737.
22. Cain WT, Oppenheimer JJ. The misconception of using floating patterns as an accurate means of measuring the contents of metered-dose inhaler devices. Ann Allergy Asthma Immunol 2001;87:417-9.
23. Barry PW, O'Callaghan C. New formulation metered dose inhaler increases breath alcohol levels. Respir Med 1999;93:167-8.
24. Levin PD, Levin D, Avidan A. Medical aerosol propellant interference with infrared anaesthetic gas monitors. Br J Anaesth 2004;92:865-9.
25. Williams G. Moisture transport into chlorofluorocarbon-free metered dose inhalers. J Allergy Clin Immunol 1999;104:S227-S229.
26. Schultz RK. Drug delivery characteristics of metered-dose inhalers. J Allergy Clin Immunol 1995;96:284-7.
27. Ross DL, Gabrio BJ. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. J Aerosol Med 1999;12:151-60.
28. Colice GL, Klinger NM, Ekholm BP, Dockhorn RJ. Proventil HFA prevents exercise-induced bronchoconstriction in children. J Asthma 1999;36:671-6.
29. Shapiro G, Bronsky E, Murray A, Barnhart F, VanderMeer A, Reisner C. Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma. Arch Pediatr Adolesc Med 2000;154:1219-25.
30. Shapiro GS, Klinger NM, Ekholm BP, Colice GL. Comparable bronchodilation with hydrofluoroalkane-134a (HFA) albuterol and chlorofluorocarbons-11/12 (CFC) albuterol in children with asthma. J Asthma 2000;37:667-75.
31. Dockhorn R, Vanden Burgt JA, Ekholm BP, Donnell D, Cullen MT. Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose inhaler and a conventional chlorofluorocarbon inhaler in patients with asthma. J Allergy Clin Immunol 1995;96:50-6.
32. Langley SJ, Sykes AP, Batty EP, Masterson CM, Woodcock A. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Ann Allergy Asthma Immunol 2002;88:488-93.
33. Dockhorn RJ, Wagner DE, Burgess GL, et al. Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin. Ann Allergy Asthma Immunol 1997;79:85-8.
34. Hawksworth RJ, Sykes AP, Faris M, Mant T, Lee TH. Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. Ann Allergy Asthma Immunol 2002;88:473-7.
35. Ramsdell JW, Colice GL, Ekholm BP, Klinger NM. Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma. Ann Allergy Asthma Immunol 1998;81:593-9.
36. Kleerup EC, Tashkin DP, Cline AC, Ekholm BP. Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metered-dose inhaler in patients with asthma. Chest 1996;109:702-7.
37. Bleecker ER, Tinkelman DG, Ramsdell J, et al. Proventil HFA provides bronchodilation comparable to Ventolin over 12 weeks of regular use in asthmatics. Chest 1998;113:283-9.
38. Tinkelman DG, Bleecker ER, Ramsdell J, et al. Proventil HFA and Ventolin have similar safety profiles during regular use. Chest 1998;113:290-6.
39. Ahrens RC, Hendeles L, Clarke WR, et al. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler: a bioassay using methacholine. Am J Respir Crit Care Med 1999;160:1238-43.
40. Stewart BA, Ahrens RC, Carrier S, et al. Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin. Chest 2000;117:714-21.
41. 2-agonist. Am J Respir Crit Care Med 1999;160:354-7.
42. Leach C. Safety assessment of the HFA propellant and the new inhaler. Eur Respir Rev 1997;7:35-6.
43. Harrison LI, Donnell D, Simmons JL, Ekholm BP, Cooper KM, Wyld PJ. Twenty-eight-day double-blind safety study of an HFA-134a inhalation aerosol system in healthy subjects. J Pharm Pharmacol 1996;48:596-600.
44. Bronsky E, Ekholm BP, Klinger NM, Colice GL. Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. J Asthma 1999;36:107-14.
45. Lumry W, Noveck R, Weinstein S, et al. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma. Ann Allergy Asthma Immunol 2001;86:297-303.
46. Salat D, Popov D, Sykes AP. Equivalence of salbutamol 200 μg four times daily propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Respir Med 2000;94:Suppl B:S22-S28.
47. Baumgarten CR, Dorow P, Weber HH, Gebhardt R, Kettner J, Sykes AP. Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. Respir Med 2000;94:Suppl B:S17-S21.
48. Craig-McFeely PM, Wilton LV, Soriano JB, Maier WC, Shakir SA. Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England. Int J Clin Pharmacol Ther 2003;41:67-76.
49. Ayres JG, Frost CD, Holmes WF, Williams DR, Ward SM. Postmarketing surveillance study of a non-chlorofluorocarbon inhaler according to the Safety Assessment of Marketed Medicines guidelines. BMJ 1998;317:926-30.